Loperfido Federica, Sottotetti Francesca, Bianco Irene, El Masri Dana, Maccarini Beatrice, Ferrara Chiara, Limitone Antonio, Cena Hellas, De Giuseppe Rachele
Laboratory of Dietetics and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100, Pavia, Italy.
Haleon Italy S.R.L, SocietàUnipersonale, Via Monte Rosa 91, 20149, Milan, MI, Italy.
Reprod Health. 2025 Jan 31;22(1):13. doi: 10.1186/s12978-025-01953-y.
Neural tube defects (NTDs), well-known consequences of folate deficiency, are the second most common cause of serious birth defects, affecting approximately one in a thousand pregnancies in Europe. Maternal folate deficiency before conception and during early pregnancy has been suggested as the most important preventable risk factor for NTDs; thus women should be supplemented before conception with 0.4 mg of folic acid (FA) until the first trimester of gestation. Findings have described a positive association between elevated Body Mass Index (BMI) and birth defect risk; data on plasma folate levels in pregnant women with obesity have shown values lower than recommended because of a state of chronic low-grade inflammation, resulting in increased metabolic demands. Nowadays, disparities exist regarding the recommended dose of FA in women at risk, including women of childbearing age with excessive weight. Therefore, this systematic review aimed to investigate if European childbearing age/pregnant women with overweight/obesity are supplemented according to the current country-specific FA recommendations and whether the dosage of 5 mg recommended for pregnant women with obesity is effective in preventing NTDs.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. An electronic database search of manuscripts was carried out in Web of Sciences, PubMed and Medline. The quality of the included studies was assessed by using the Quality Assessment for Diverse Studies statement.
Out of 1718 records identified, 8 manuscripts met all the inclusion criteria. Overall, the results showed that pregnant women with obesity adherent to FA recommendations ranged between 4% and 9.5%. Furthermore, the majority (61%) started the supplementation after conception, highlighting that European pregnant women are not particularly adherent to recommendations during the period of greatest need.
The scarce adherence to the current guidelines shows an urgent need to standardize the recommendations across European countries. Particularly, women of childbearing age with excess weight should be monitored assessing serum folate, RBC folate, and homocysteine levels developing tailored supplementation protocols, to counteract the occurrence of NTDs.
神经管缺陷(NTDs)是叶酸缺乏的著名后果,是严重出生缺陷的第二大常见原因,在欧洲约每千次怀孕中就有一例受影响。受孕前和孕早期的母体叶酸缺乏被认为是神经管缺陷最重要的可预防风险因素;因此,女性应在受孕前补充0.4毫克叶酸(FA),直至妊娠早期。研究结果描述了体重指数(BMI)升高与出生缺陷风险之间的正相关;肥胖孕妇血浆叶酸水平的数据显示,由于慢性低度炎症状态,其值低于推荐值,导致代谢需求增加。如今,对于高危女性,包括超重的育龄女性,叶酸的推荐剂量存在差异。因此,本系统评价旨在调查欧洲育龄/超重/肥胖孕妇是否按照当前各国特定的叶酸推荐进行补充,以及推荐给肥胖孕妇的5毫克剂量在预防神经管缺陷方面是否有效。
遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南。在Web of Sciences、PubMed和Medline上对稿件进行电子数据库检索。使用不同研究质量评估声明对纳入研究的质量进行评估。
在识别出的1718条记录中,8篇稿件符合所有纳入标准。总体而言,结果显示,遵循叶酸推荐的肥胖孕妇比例在4%至9.5%之间。此外,大多数(61%)在受孕后开始补充,这突出表明欧洲孕妇在最需要的时期并没有特别遵循推荐。
对当前指南的依从性差表明迫切需要在欧洲各国规范推荐。特别是,应监测超重的育龄女性,评估血清叶酸、红细胞叶酸和同型半胱氨酸水平,制定量身定制的补充方案,以预防神经管缺陷的发生。